Decoding TB Drug Resistance: Precision Molecular Detection for Targeted Treatment.
Delivering actionable resistance profiles for the right treatment from day one.
Founded in 2015 in Stockholm, Sweden, EMPE Diagnostics emerged from the scientific excellence of the Karolinska Institute.
We are dedicated to confronting the global burden of tuberculosis (TB) through advanced molecular diagnostics engineered specifically to address the complexities of molecular drug resistance testing.
Our mission goes beyond basic detection. By simultaneously identifying TB and delivering comprehensive antibiotic resistance profiling in a single, high-precision test, we empower clinicians to stay ahead of antimicrobial resistance (AMR) and ensure patients receive targeted treatment from day one.
Our vision is a world free from TB, driven by expert-level diagnostic precision and actionable resistance data for clinicians everywhere.
With a strong focus on international markets, particularly in India, where more than 2.7 million new TB cases are reported each year, EMPE Diagnostics plays a vital role in addressing drug-resistant tuberculosis at scale.
Our CDSCO-approved IVD product (India Regulatory Authorities) is manufactured at scale at our dedicated facility in Hyderabad.
Backed by our ISO 13485:2016 certification and full compliance with “Make in India” requirements, we are uniquely positioned to participate in national programs and government tenders focused on overcoming drug-resistant TB.
At the leading edge of medical innovation, we design, develop, and manufacture molecular diagnostic tools for highly accurate tuberculosis detection and comprehensivegenotypic antimicrobial resistance profiling.
At the core of our innovation is Pli-RCA (Padlock probe-linked Rolling Circle Amplification), our proprietary molecular detection platform.
Pli-RCA combines advanced padlock probe design with rolling circle amplification and specialized enzymatic biochemistry to enable highly sensitive and specific detection of resistance-associated mutations in the Mycobacterium tuberculosis complex (MTBC).
Leveraging the power of this platform, we have deployed a rigorous molecular test that detects MTBC alongside key genetic markers conferring resistance to rifampicin and isoniazid.
Building on this foundation, we are actively expanding our panel with the introduction of a third critical antibiotic class: fluoroquinolones.
As we continue to innovate, our teams are hard at work adding bedaquiline and linezolid detection, delivering an uncompromising, in-depth solution for comprehensive genotypic TB resistance profiling.
While our primary focus is addressing complex drug-resistant tuberculosis, we are actively expanding the Pli-RCA pipeline across broader infectious and non-infectious disease areas, enabling precise detection across a wide range of clinical challenges.
EMPE Diagnostics is proud to be supported by leading global organizations and investors who share our commitment to eliminating TB. We have received grant funding from both the European Innovation Council (EIC) and the Gates Foundation — making us the first company to be backed by both these prestigious institutions.
Deep resistance profiling
Preventing therapeutic failure
Early detection
Fast, Accessible, Affordable
Improved diagnostic confidence
High sensitivity & specificity
Efficient workflow
Streamlined for routine molecular laboratories
Automation compatible
Eliminate handling erros, increased throughput
Platform independent
Designed for use on your laboratory equipment
tb diagnostics
molecular diagnostics molecular diagnostics
|
tb diagnostics |
molecular diagnostics
rapid diagnostics
| tb diagnostics |